Search This Blog

 


side-effects when given with sympathomimetics, inotropic.

Theoretical

▶ Entacapone is predicted to increase the risk of cardiovascular

side-effects when given with sympathomimetics, vasoconstrictor

(adrenaline/epinephrine, noradrenaline/norepinephrine)

o .

Study

Enteral feeds

▶ Antacids (aluminium hydroxide) increase the risk of blocked

enteral or nasogastric tubes when given with

o

enteral feeds.

Study

▶ Enteral feeds decrease the absorption of antiepileptics

(phenytoin).rStudy

▶ Enteral feeds (vitamin-K containing) potentially decrease the

anticoagulant effect of coumarins.rAnecdotal

▶ Enteral feeds (vitamin-K containing) potentially decrease the

effects of phenindione.rTheoretical

▶ Enteral feeds decrease the exposure to quinolones

(ciprofloxacin).oStudy

▶ Sucralfate increases the risk of blocked enteral or nasogastric

tubes when given with enteral feeds. Separate administration

by 1 hour.oStudy

▶ Enteral feeds

Study

decrease the exposure to theophylline.o

Enzalutamide

GENERAL INFORMATION Caution with concurrent

chemotherapy—safety and efficacy not established.

▶ Enzalutamide is predicted to markedly decrease the exposure

to abemaciclib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

abiraterone. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

aldosterone antagonists (eplerenone). Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

alprazolam. Adjust dose.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

Study

antiarrhythmics (disopyramide, dronedarone). Avoid.r

▶ Enzalutamide is predicted to decrease the efficacy of

antiarrhythmics (propafenone).oStudy

▶ Enzalutamide is predicted to decrease the exposure to

anticholinesterases, centrally acting (donepezil).nStudy

▶ Enzalutamide is predicted to slightly decrease the exposure to

antiepileptics (brivaracetam).oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

Study

antiepileptics (perampanel). Monitor and adjust dose.o ▶ Enzalutamide is predicted to decrease the exposure to

antifungals, azoles (isavuconazole). Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

Study

antimalarials (artemether) (with lumefantrine). Avoid.r

▶ Enzalutamide is predicted to decrease the concentration of

antimalarials (piperaquine). Avoid.oTheoretical

▶ Enzalutamide is predicted to moderately decrease the

exposure to apixaban. Use with caution or avoid.rStudy

▶ Enzalutamide moderately decreases the exposure to

apremilast. Avoid.rStudy

▶ Enzalutamide is predicted to markedly decrease the exposure

to aprepitant. Avoid.oStudy

▶ Enzalutamide is predicted to moderately decrease the

o

exposure to aripiprazole. Adjust aripiprazole dose, p. 395.

Study

▶ Enzalutamide is predicted to decrease the exposure to axitinib.

Avoid or adjust dose.oStudy

▶ Enzalutamide

r

decreases the exposure to bedaquiline. Avoid.

Study

▶ Enzalutamide is predicted to decrease the exposure to

bictegravir. Avoid.oStudy

▶ Enzalutamide slightly decreases the exposure to bortezomib.

Avoid.rStudy

▶ Enzalutamide

Study

affects the exposure to bosentan. Avoid.r

▶ Enzalutamide is predicted to very markedly decrease the

exposure to bosutinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

brigatinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

buspirone. Use with caution and adjust dose.rStudy

▶ Enzalutamide moderately decreases the exposure to

cabozantinib. Avoid.oStudy

▶ Enzalutamide is predicted to decrease the exposure to calcium

channel blockers (amlodipine, felodipine, lacidipine,

lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and

adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to calcium

channel blockers (diltiazem, verapamil).rStudy

▶ Enzalutamide is predicted to decrease the exposure to

cannabis extract. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

cariprazine. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

ceritinib. Avoid.rStudy

▶ Enzalutamide

r

decreases the concentration of ciclosporin.

Study

▶ Enzalutamide

o

is predicted to alter the effects of cilostazol.

Theoretical

▶ Enzalutamide is predicted to decrease the exposure to

cinacalcet. Monitor and adjust dose.oStudy

1450 Encorafenib — Enzalutamide BNF 78

Interactions | Appendix 1

A1

▶ Enzalutamide decreases the exposure to clomethiazole.

Monitor and adjust dose.oStudy

▶ Clopidogrel moderately increases the exposure to

enzalutamide

Study

. Avoid or adjust enzalutamide dose, p. 947.r

▶ Enzalutamide is predicted to decrease the exposure to

clozapine.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

cobicistat. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

cobimetinib. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

corticosteroids (budesonide, deflazacort, dexamethasone,

fludrocortisone, hydrocortisone, methylprednisolone,

prednisolone, triamcinolone)

o

. Monitor and adjust dose.

Study

▶ Enzalutamide is predicted to decrease the exposure to

corticosteroids (fluticasone).qTheoretical

▶ Enzalutamide potentially decreases the exposure to coumarins.

Avoid or adjust dose and monitor INR.rStudy

▶ Enzalutamide is predicted to markedly decrease the exposure

to crizotinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

dabrafenib. Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

darifenacin.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

dasabuvir. Avoid.rTheoretical

▶ Enzalutamide is predicted to markedly decrease the exposure

to dasatinib. Avoid.rStudy

▶ Enzalutamide is predicted to slightly decrease the exposure to

delamanid. Avoid.oStudy

▶ Enzalutamide decreases the exposure to dolutegravir. Adjust

dose.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

doravirine. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to elbasvir.

Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

eliglustat. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the concentration of

elvitegravir. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

encorafenib.rTheoretical

▶ Enzalutamide is predicted to decrease the effects of

ergotamine.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

erlotinib. Avoid or adjust erlotinib dose, p. 979.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

esketamine. Adjust dose.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

etravirine. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the concentration of

everolimus. Avoid or adjust dose.rStudy

▶ Enzalutamide moderately decreases the exposure to

exemestane.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

fesoterodine. Avoid.oStudy

▶ Fibrates (gemfibrozil) moderately increase the exposure to

enzalutamide

Study

. Avoid or adjust enzalutamide dose, p. 947.r

▶ Enzalutamide is predicted to decrease the exposure to

fingolimod.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

fosaprepitant. Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

gefitinib. Avoid.rStudy

▶ Enzalutamide is predicted to greatly decrease the

concentration of glecaprevir. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

grazoprevir. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the concentration of

guanfacine. Adjust guanfacine dose, p. 352.oStudy

▶ Enzalutamide decreases the concentration of haloperidol.

Adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

ibrutinib. Avoid or adjust ibrutinib dose, p. 983.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

idelalisib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

imatinib. Avoid.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

irinotecan. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

ivabradine. Adjust dose.oTheoretical

▶ Enzalutamide is predicted to moderately to markedly decrease

the exposure to ivacaftor. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

ixazomib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

lapatinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

linagliptin.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

lomitapide. Monitor and adjust dose.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

lurasidone. Avoid.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

macitentan. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

maraviroc. Adjust dose.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

midazolam. Monitor and adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

midostaurin. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

mirtazapine. Adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

montelukast.nStudy

▶ Enzalutamide is predicted to markedly decrease the exposure

to naloxegol. Avoid.oStudy

▶ Enzalutamide is predicted to slightly decrease the exposure to

nateglinide.nStudy

▶ Enzalutamide is predicted to decrease the exposure to

netupitant. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

nevirapine.rTheoretical

▶ Enzalutamide is predicted to moderately decrease the

exposure to nilotinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

nitisinone. Adjust dose.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

olaparib. Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

ombitasvir. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

ondansetron.oStudy

▶ Enzalutamide is predicted to decrease the exposure to opioids

(alfentanil, fentanyl).oStudy

▶ Enzalutamide is predicted to decrease the exposure to opioids

(buprenorphine). Monitor and adjust dose.oTheoretical

▶ Enzalutamide decreases the exposure to opioids (methadone).

Monitor and adjust dose.rStudy

▶ Enzalutamide is predicted to decrease the exposure to opioids

(oxycodone). Monitor and adjust dose.oStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to osimertinib. Avoid.oStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to ospemifene.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

palbociclib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

paliperidone. Monitor and adjust dose.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

panobinostat. Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

paritaprevir

Study

(with ritonavir and ombitasvir). Avoid.r

▶ Enzalutamide is predicted to decrease the exposure to

pazopanib. Avoid.rTheoretical

BNF 78 Enzalutamide — Enzalutamide 1451

Interactions | Appendix 1

A1

Enzalutamide (continued)

▶ Enzalutamide is predicted to decrease the exposure to

r

phosphodiesterase type-5 inhibitors (avanafil, tadalafil). Avoid.

Study

▶ Enzalutamide is predicted to decrease the exposure to

o

phosphodiesterase type-5 inhibitors (sildenafil, vardenafil).

Theoretical

▶ Enzalutamide is predicted to moderately to markedly decrease

the exposure to pibrentasvir. Avoid.rStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to pitolisant.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

ponatinib. Avoid.oTheoretical

▶ Enzalutamide is predicted to markedly decrease the exposure

to praziquantel. Avoid.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

quetiapine.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

ranolazine. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

reboxetine.oAnecdotal

▶ Enzalutamide is predicted to decrease the exposure to

regorafenib. Avoid.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

repaglinide

Study

. Monitor blood glucose and adjust dose.o ▶ Enzalutamide is predicted to markedly decrease the exposure

to ribociclib. Avoid.rStudy

▶ Enzalutamide markedly decreases the exposure to rilpivirine.

Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

risperidone. Adjust dose.oStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to rivaroxaban. Avoid unless patient can be

monitored for signs of thrombosis.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

roflumilast. Avoid.oStudy

▶ Enzalutamide is predicted to markedly decrease the exposure

to rolapitant. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

ruxolitinib. Monitor and adjust dose.oStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to saxagliptin.oStudy

▶ Enzalutamide is predicted to decrease the concentration of

sirolimus. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

solifenacin.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

sorafenib.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to statins

(simvastatin).rStudy

▶ Enzalutamide is predicted to decrease the exposure to

sunitinib. Avoid or adjust sunitinib dose, p. 999.oStudy

▶ Enzalutamide decreases the concentration of tacrolimus.

Monitor and adjust dose.rStudy

▶ Enzalutamide is predicted to decrease the exposure to taxanes

(cabazitaxel, paclitaxel). Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to taxanes

(docetaxel).rTheoretical

▶ Enzalutamide is predicted to decrease the concentration of

temsirolimus. Avoid.rStudy

▶ Enzalutamide decreases the exposure to tetracyclines

(doxycycline). Monitor and adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

tezacaftor. Avoid.rTheoretical

▶ Enzalutamide is predicted to markedly decrease the exposure

to ticagrelor. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

tivozanib.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

tofacitinib. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

tolvaptan

r

. Use with caution or avoid depending on indication.

Study

▶ Enzalutamide is predicted to decrease the exposure to

toremifene. Adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

trabectedin. Avoid.rTheoretical

▶ Enzalutamide is predicted to markedly decrease the exposure

rto ulipristal. Avoid and for 4 weeks after stopping ulipristal.

Theoretical

▶ Enzalutamide is predicted to decrease the exposure to

vandetanib. Avoid.oStudy

▶ Enzalutamide is predicted to moderately decrease the

exposure to velpatasvir. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

vemurafenib. Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

venetoclax. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to vinca

alkaloids (vinblastine, vincristine, vindesine).rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to vinca

alkaloids (vinflunine). Avoid.rTheoretical

▶ Enzalutamide is predicted to decrease the exposure to vinca

alkaloids

Theoretical

(vinorelbine). Use with caution or avoid.r

▶ Enzalutamide is predicted to decrease the exposure to

vismodegib. Avoid.oTheoretical

▶ Enzalutamide is predicted to decrease the exposure to

vortioxetine. Monitor and adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the concentration of

voxilaprevir. Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

zopiclone. Adjust dose.oStudy

Ephedrine → see sympathomimetics, vasoconstrictor

Epirubicin → see anthracyclines

Eplerenone → see aldosterone antagonists

Epoetin alfa → see TABLE 5 p. 1375 (thromboembolism), TABLE 16

p. 1379 (increased serum potassium)

Epoetin beta → see TABLE 5 p. 1375 (thromboembolism), TABLE 16

p. 1379 (increased serum potassium)

Epoetin zeta → see TABLE 5 p. 1375 (thromboembolism), TABLE 16

p. 1379 (increased serum potassium)

Epoprostenol → see TABLE 4 p. 1375 (antiplatelet effects)

Eprosartan → see angiotensin-II receptor antagonists

Eptifibatide → see TABLE 4 p. 1375 (antiplatelet effects)

Ergocalciferol → see vitamin D substances

Ergometrine

▶ Antiarrhythmics (dronedarone) are predicted to increase the

risk of ergotism when given with

Theoretical

ergometrine.r

▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to increase the risk of ergotism when given with

ergometrine.rTheoretical

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the risk of ergotism when given with

ergometrine. Avoid.rTheoretical

▶ Antifungals, azoles (miconazole) are predicted to increase the

exposure to ergometrine. Avoid.oTheoretical

▶ Aprepitant is predicted to increase the risk of ergotism when

given with ergometrine.rTheoretical

▶ Beta blockers, non-selective are predicted to increase the risk

of peripheral vasoconstriction when given with

r

ergometrine.

No comments:

Post a Comment

اكتب تعليق حول الموضوع

mcq general

 

Search This Blog